Free Trial

AstraZeneca (AZN) Competitors

AstraZeneca logo
$69.68 -0.24 (-0.34%)
Closing price 05/21/2025 04:00 PM Eastern
Extended Trading
$69.79 +0.11 (+0.16%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AZN vs. NVO, NVS, SNY, GSK, TAK, ARGX, BNTX, ONC, TEVA, and SMMT

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novo Nordisk A/S (NVO), Novartis (NVS), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

AstraZeneca vs.

Novo Nordisk A/S (NYSE:NVO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Novo Nordisk A/S currently has a consensus price target of $135.00, indicating a potential upside of 97.97%. AstraZeneca has a consensus price target of $88.00, indicating a potential upside of 26.29%. Given Novo Nordisk A/S's higher probable upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
2 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.38
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.10

Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$303.14B1.01$14.64B$3.3820.18
AstraZeneca$54.98B3.93$7.04B$2.4927.98

In the previous week, Novo Nordisk A/S had 36 more articles in the media than AstraZeneca. MarketBeat recorded 65 mentions for Novo Nordisk A/S and 29 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.53 beat Novo Nordisk A/S's score of 0.55 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
28 Very Positive mention(s)
9 Positive mention(s)
14 Neutral mention(s)
12 Negative mention(s)
1 Very Negative mention(s)
Positive
AstraZeneca
25 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novo Nordisk A/S received 371 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 60.00% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
Novo Nordisk A/SOutperform Votes
434
61.74%
Underperform Votes
269
38.26%
AstraZenecaOutperform Votes
63
60.00%
Underperform Votes
42
40.00%

Novo Nordisk A/S has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Novo Nordisk A/S has a net margin of 34.81% compared to AstraZeneca's net margin of 13.01%. Novo Nordisk A/S's return on equity of 84.68% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S34.81% 84.68% 26.29%
AstraZeneca 13.01%32.23%12.31%

Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.4%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 3.0%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. AstraZeneca pays out 82.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

Novo Nordisk A/S beats AstraZeneca on 13 of the 21 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$216.09B$6.52B$5.37B$8.39B
Dividend Yield3.03%2.65%5.22%4.10%
P/E Ratio30.838.9226.8419.71
Price / Sales3.93253.80392.34117.39
Price / Cash11.7965.8538.2534.62
Price / Book5.296.466.794.50
Net Income$7.04B$143.98M$3.23B$248.18M
7 Day Performance2.53%2.03%1.53%0.20%
1 Month Performance2.67%4.11%10.06%12.37%
1 Year Performance-11.57%-2.87%16.72%7.04%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
3.52 of 5 stars
$69.68
-0.3%
$88.00
+26.3%
-12.0%$216.09B$54.98B30.8383,500Positive News
NVO
Novo Nordisk A/S
4.6803 of 5 stars
$66.68
+3.6%
$135.00
+102.5%
-49.6%$299.23B$303.14B20.2754,400Trending News
NVS
Novartis
1.4972 of 5 stars
$110.27
+0.6%
$123.38
+11.9%
+9.7%$232.94B$53.22B18.75101,700Positive News
SNY
Sanofi
4.0406 of 5 stars
$52.08
+0.8%
$63.33
+21.6%
+8.1%$131.57B$45.17B20.9291,600Positive News
GSK
GSK
1.9413 of 5 stars
$37.82
+0.5%
$40.58
+7.3%
-13.4%$78.03B$31.53B23.7990,100Positive News
TAK
Takeda Pharmaceutical
3.32 of 5 stars
$14.21
+0.7%
N/A+8.6%$45.21B$4.58T35.5347,300Positive News
ARGX
argenx
3.2942 of 5 stars
$574.29
+1.5%
$698.11
+21.6%
+64.0%$35.07B$2.58B-652.60650Positive News
Gap Up
BNTX
BioNTech
2.8009 of 5 stars
$97.25
+4.8%
$142.08
+46.1%
+7.6%$23.38B$2.75B-46.313,080Trending News
ONC
Beigene
2.6864 of 5 stars
$232.19
+1.7%
$319.00
+37.4%
N/A$23.00B$4.18B-28.189,000Gap Down
TEVA
Teva Pharmaceutical Industries
3.2848 of 5 stars
$16.91
-0.2%
$24.43
+44.5%
-0.1%$19.17B$16.62B-11.6636,800Positive News
Options Volume
SMMT
Summit Therapeutics
3.1705 of 5 stars
$23.70
-0.7%
$37.40
+57.8%
+478.8%$17.60B$700,000.00-84.64110Positive News

Related Companies and Tools


This page (NASDAQ:AZN) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners